Filing Flows › Arcutis Biotherapeutics (ARQT) › R&D spending
Arcutis Biotherapeutics (ARQT) R&D spending by quarter
Arcutis Biotherapeutics' R&D spending was $22.4M in Q3 2026 (third quarter 2026), +10% from Q2 2026. Over the last 7 quarters it ranged from $17.5M (Q1 2025) to $30.6M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $22.4M | +10% | +14% |
| Q2 2026 | $20.4M | -34% | +5% |
| Q1 2026 | $30.6M | +50% | +75% |
| Q4 2025 | $20.5M | +4% | — |
| Q3 2025 | $19.6M | +0.8% | — |
| Q2 2025 | $19.5M | +11% | — |
| Q1 2025 | $17.5M | — | — |
Q3 2026 at a glance
Arcutis Biotherapeutics, Q3 2026: revenue $144M (+45% year over year), operating margin 6.6%, net earnings $8.8M, operating cash flow $18.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Arcutis Biotherapeutics' R&D spending?
Arcutis Biotherapeutics' R&D spending was $22.4M in Q3 2026 (third quarter 2026), +10% from Q2 2026.
How has Arcutis Biotherapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $17.5M (Q1 2025) to $30.6M (Q1 2026).
Q3 2026 results → · How Arcutis Biotherapeutics makes money →